103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
SB0218

 

Introduced 1/31/2023, by Sen. Ann Gillespie

 

SYNOPSIS AS INTRODUCED:
 
225 ILCS 95/4  from Ch. 111, par. 4604
225 ILCS 95/5.5
225 ILCS 95/6  from Ch. 111, par. 4606
225 ILCS 95/7  from Ch. 111, par. 4607
225 ILCS 95/7.5
225 ILCS 95/7.7
225 ILCS 95/7.8 new
225 ILCS 95/7.9 new
225 ILCS 95/17  from Ch. 111, par. 4617
225 ILCS 95/21  from Ch. 111, par. 4621
720 ILCS 570/102  from Ch. 56 1/2, par. 1102
720 ILCS 570/303.05

    Amends the Physician Assistant Practice Act of 1987. Changes the definition of "physician assistant", "physician assistant practice", "board", and "collaborating physician". Provides that a physician assistant shall be deemed by law to possess the ability to prescribe, dispense, order, administer, and procure drugs and medical devices without delegation of such authority by a physician. Provides that such ability shall include the prescribing of Schedule II, III, IV, and V controlled substances. Provides that to prescribe Schedule II, III, IV, or V controlled substances under the Act, a physician assistant shall obtain a mid-level practitioner controlled substances license. Provides that when a written collaboration agreement is required under the Act, delegation of prescriptive authority by a physician is not required. Provides that a physician assistant who files with the Department of Financial and Professional Regulation a notarized attestation of completion of at least 250 hours of continuing education or training and at least 2,000 hours of clinical experience after first attaining national certification shall not require a written collaborative agreement. Provides the specified scope of practice of a physician assistant with optimal practice authority. Provides that a physician assistant shall be able to hold more than one professional position. Makes changes in provisions concerning the physician assistant title, collaboration requirements, and the written collaborative agreement. Makes other changes and corresponding changes to the Act and to the Illinois Controlled Substances Act.


LRB103 25028 AMQ 51362 b

 

 

A BILL FOR

 

SB0218LRB103 25028 AMQ 51362 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Physician Assistant Practice Act of 1987 is
5amended by changing Sections 4, 5.5, 6, 7, 7.5, 7.7, 17, and 21
6and by adding Sections 7.8 and 7.9 as follows:
 
7    (225 ILCS 95/4)  (from Ch. 111, par. 4604)
8    (Section scheduled to be repealed on January 1, 2028)
9    Sec. 4. Definitions. In this Act:
10    1. "Department" means the Department of Financial and
11Professional Regulation.
12    2. "Secretary" means the Secretary of Financial and
13Professional Regulation.
14    3. "Physician assistant" means any person not holding an
15active license or permit issued by the Department pursuant to
16the Medical Practice Act of 1987 who has been certified as a
17physician assistant by the National Commission on the
18Certification of Physician Assistants or equivalent successor
19agency and performs procedures in collaboration with a
20physician as defined in this Act. A physician assistant may
21perform such procedures within the specialty of the
22collaborating physician, except that such physician shall
23exercise such direction, collaboration, and control over such

 

 

SB0218- 2 -LRB103 25028 AMQ 51362 b

1physician assistants as will assure that patients shall
2receive quality medical care. Physician assistants shall be
3capable of performing a variety of tasks within the specialty
4of medical care in collaboration with a physician.
5Collaboration with the physician assistant shall not be
6construed to necessarily require the personal presence of the
7collaborating physician at all times at the place where
8services are rendered, as long as there is communication
9available for consultation by radio, telephone or
10telecommunications within established guidelines as determined
11by the physician/physician assistant team. The collaborating
12physician may delegate tasks and duties to the physician
13assistant. Delegated tasks or duties shall be consistent with
14physician assistant education, training, and experience. The
15delegated tasks or duties shall be specific to the practice
16setting and shall be implemented and reviewed under a written
17collaborative agreement established by the physician or
18physician/physician assistant team. A physician assistant,
19acting as an agent of the physician, shall be permitted to
20transmit the collaborating physician's orders as determined by
21the institution's by-laws, policies, procedures, or job
22description within which the physician/physician assistant
23team practices. Physician assistants shall practice only in
24accordance with a written collaborative agreement.
25    Any person who holds an active license or permit issued
26pursuant to the Medical Practice Act of 1987 shall have that

 

 

SB0218- 3 -LRB103 25028 AMQ 51362 b

1license automatically placed into inactive status upon
2issuance of a physician assistant license. Any person who
3holds an active license as a physician assistant who is issued
4a license or permit pursuant to the Medical Practice Act of
51987 shall have his or her physician assistant license
6automatically placed into inactive status.
7    3.5. "Physician assistant practice" means the performance
8of any legal medical service for which the physician assistant
9has been prepared by the physician assistant's education,
10training, and experience and is competent to perform as
11determined by the practice through employment agreement or
12credentialing and privileging systems of licensed facilities.
13Medical and surgical services provided by a physician
14assistant include, but are not limited to:
15        (A) obtaining and performing comprehensive health
16    histories and physical examinations;
17        (B) evaluating, diagnosing, managing, and providing
18    medical treatment;
19        (C) ordering, performing, and interpreting diagnostic
20    studies and therapeutic procedures;
21        (D) educating patients on health promotion and disease
22    prevention;
23        (E) providing consultation upon request;
24        (F) writing medical orders;
25        (G) prescribing, dispensing, ordering, administering,
26    and procuring drugs and medical devices; and

 

 

SB0218- 4 -LRB103 25028 AMQ 51362 b

1        (H) assisting in surgery procedures within the
2    specialty of the collaborating physician. Physician
3    assistants shall be capable of performing a variety of
4    tasks within the specialty of medical care of the
5    collaborating physician. Collaboration with the physician
6    assistant shall not be construed to necessarily require
7    the personal presence of the collaborating physician at
8    all times at the place where services are rendered, as
9    long as there is communication available for consultation
10    by radio, telephone, telecommunications, or electronic
11    communications. The collaborating physician may delegate
12    tasks and duties to the physician assistant. Delegated
13    tasks or duties shall be consistent with physician
14    assistant education, training, and experience. The
15    delegated tasks or duties shall be specific to the
16    practice setting and shall be implemented and reviewed
17    under a written collaborative agreement established by the
18    physician or physician/physician assistant team. A
19    physician assistant shall be permitted to transmit the
20    collaborating physician's orders as determined by the
21    institution's bylaws, policies, or procedures or the job
22    description within which the physician/physician assistant
23    team practices. Physician assistants shall practice only
24    in accordance with a written collaborative agreement,
25    except as provided in Section 7.5 of this Act.
26    4. "Board" means the Illinois State Medical Board Medical

 

 

SB0218- 5 -LRB103 25028 AMQ 51362 b

1Licensing Board constituted under the Medical Practice Act of
21987.
3    5. (Blank).
4    6. "Physician" means a person licensed to practice
5medicine in all of its branches under the Medical Practice Act
6of 1987.
7    7. "Collaborating physician" means the physician who,
8within his or her specialty and expertise, may delegate a
9variety of tasks and procedures to the physician assistant.
10Such tasks and procedures shall be delegated in accordance
11with a written collaborative agreement when such agreement is
12required under this Act.
13    8. (Blank).
14    9. "Address of record" means the designated address
15recorded by the Department in the applicant's or licensee's
16application file or license file maintained by the
17Department's licensure maintenance unit.
18    10. "Hospital affiliate" means a corporation, partnership,
19joint venture, limited liability company, or similar
20organization, other than a hospital, that is devoted primarily
21to the provision, management, or support of health care
22services and that directly or indirectly controls, is
23controlled by, or is under common control of the hospital. For
24the purposes of this definition, "control" means having at
25least an equal or a majority ownership or membership interest.
26A hospital affiliate shall be 100% owned or controlled by any

 

 

SB0218- 6 -LRB103 25028 AMQ 51362 b

1combination of hospitals, their parent corporations, or
2physicians licensed to practice medicine in all its branches
3in Illinois. "Hospital affiliate" does not include a health
4maintenance organization regulated under the Health
5Maintenance Organization Act.
6    11. "Email address of record" means the designated email
7address recorded by the Department in the applicant's
8application file or the licensee's license file, as maintained
9by the Department's licensure maintenance unit.
10(Source: P.A. 102-1117, eff. 1-13-23.)
 
11    (225 ILCS 95/5.5)
12    (Section scheduled to be repealed on January 1, 2028)
13    Sec. 5.5. Billing. A physician assistant may shall not be
14allowed to personally bill patients and or in any way charge
15for services. The employer of a physician assistant may bill
16and charge for services rendered by the physician assistant.
17All claims for services rendered by the physician assistant
18shall be submitted using the physician assistant's national
19provider identification number as the rendering provider, with
20the exception of when optional billing provisions, such as
21incident to, split, or shared visit billing, are being used
22whenever appropriate. Payment for services rendered by a
23physician assistant shall be made to his or her employer if the
24payor would have made payment had the services been provided
25by a physician licensed to provide medicine in all of its

 

 

SB0218- 7 -LRB103 25028 AMQ 51362 b

1branches.
2(Source: P.A. 100-453, eff. 8-25-17; 100-559, eff. 12-8-17.)
 
3    (225 ILCS 95/6)  (from Ch. 111, par. 4606)
4    (Section scheduled to be repealed on January 1, 2028)
5    Sec. 6. Physician assistant title.
6    (a) No physician assistant shall use the title of doctor
7or , physician, or associate with his or her name or any other
8term that would indicate to other persons that he or she is
9qualified to engage in the general practice of medicine.
10    (b) A physician assistant shall verbally identify himself
11or herself as a physician assistant, including specialty
12certification, when applicable, to each patient.
13    (c) Nothing in this Act shall be construed to relieve a
14physician assistant of the professional or legal
15responsibility for the care and treatment of persons attended
16by him or her.
17    (d) (Blank). The collaborating physician shall file with
18the Department notice of employment, discharge, or
19collaboration with a physician assistant within 60 days of
20employment, discharge, or assumption of collaboration with a
21physician assistant. Nothing in this Section shall prevent a
22physician assistant from beginning his or her employment
23before the notice of employment or collaboration has been
24filed.
25(Source: P.A. 102-735, eff. 1-1-23.)
 

 

 

SB0218- 8 -LRB103 25028 AMQ 51362 b

1    (225 ILCS 95/7)  (from Ch. 111, par. 4607)
2    (Section scheduled to be repealed on January 1, 2028)
3    Sec. 7. Collaboration requirements.
4    (a) A written collaborative agreement is required for all
5physician assistants engaged in clinical practice prior to
6meeting the requirements of Section 7.9, except for physician
7assistants who practice in a hospital, hospital affiliate, or
8ambulatory surgical treatment center as provided in Section
97.7.
10    (b) A collaborating physician shall determine the number
11of physician assistants to collaborate with, provided the
12physician is able to provide adequate collaboration as
13outlined in the written collaborative agreement required under
14Section 7.5 of this Act and consideration is given to the
15nature of the physician's practice, complexity of the patient
16population, and the experience of each physician assistant. A
17collaborating physician may collaborate with a maximum of 7
18full-time equivalent physician assistants as described in
19Section 54.5 of the Medical Practice Act of 1987. As used in
20this Section, "full-time equivalent" means the equivalent of
2140 hours per week per individual. Physicians and physician
22assistants who work in a hospital, hospital affiliate, or
23ambulatory surgical treatment center as defined by Section 7.7
24of this Act are exempt from the collaborative ratio
25restriction requirements of this Section. A physician

 

 

SB0218- 9 -LRB103 25028 AMQ 51362 b

1assistant shall be able to hold more than one professional
2position. A collaborating physician shall file a notice of
3collaboration of each physician assistant according to the
4rules of the Department.
5    (c) A physician assistant shall be able to hold more than
6one professional position.
7    (d) Physician assistants shall collaborate only with
8physicians as defined in this Act who are engaged in clinical
9practice, or in clinical practice in public health or other
10community health facilities.
11    (e) Nothing in this Act shall be construed to limit the
12delegation of tasks or duties by a physician to a nurse or
13other appropriately trained personnel.
14    (f) Nothing in this Act shall be construed to prohibit the
15employment of physician assistants by a hospital, nursing home
16or other health care facility where such physician assistants
17function with under a collaborating physician.
18    (g) A physician assistant may be employed by a practice
19group or other entity employing multiple physicians at one or
20more locations. In that case, one of the physicians practicing
21at a location shall be designated the collaborating physician.
22The other physicians with that practice group or other entity
23who practice in the same general type of practice or specialty
24as the collaborating physician may collaborate with the
25physician assistant with respect to their patients.
26    (h) (b) A physician assistant licensed in this State, or

 

 

SB0218- 10 -LRB103 25028 AMQ 51362 b

1licensed or authorized to practice in any other U.S.
2jurisdiction or credentialed by his or her federal employer as
3a physician assistant, who is responding to a need for medical
4care created by an emergency or by a state or local disaster
5may render such care that the physician assistant is able to
6provide without collaboration as it is defined in this Section
7or with such collaboration as is available.
8    (i) Any physician who collaborates with a physician
9assistant providing medical care in response to such an
10emergency or state or local disaster shall not be required to
11meet the requirements set forth in this Section for a
12collaborating physician.
13(Source: P.A. 100-453, eff. 8-25-17; 100-605, eff. 1-1-19.)
 
14    (225 ILCS 95/7.5)
15    (Section scheduled to be repealed on January 1, 2028)
16    Sec. 7.5. Written collaborative agreements; prescriptive
17authority.
18    (a) A written collaborative agreement is required for all
19physician assistants to practice in the State, except as
20provided in Sections Section 7.7 and Section 7.9 of this Act.
21When a written collaborative agreement is required under this
22Act, the following shall apply:
23        (1) A written collaborative agreement shall describe
24    the working relationship of the physician assistant with
25    the collaborating physician and shall describe the

 

 

SB0218- 11 -LRB103 25028 AMQ 51362 b

1    categories of care, treatment, or procedures to be
2    provided by the physician assistant. The written
3    collaborative agreement shall promote the exercise of
4    professional judgment by the physician assistant
5    commensurate with his or her education and experience. The
6    services to be provided by the physician assistant shall
7    be services that the collaborating physician is authorized
8    to and generally provides to his or her patients in the
9    normal course of his or her clinical medical practice. The
10    written collaborative agreement need not describe the
11    exact steps that a physician assistant must take with
12    respect to each specific condition, disease, or symptom
13    but must specify which authorized procedures require the
14    presence of the collaborating physician as the procedures
15    are being performed. The relationship under a written
16    collaborative agreement shall not be construed to require
17    the personal presence of a physician at the place where
18    services are rendered. Methods of communication shall be
19    available for consultation with the collaborating
20    physician in person or by telecommunications or electronic
21    communications as set forth in the written collaborative
22    agreement. For the purposes of this Act, "generally
23    provides to his or her patients in the normal course of his
24    or her clinical medical practice" means services, not
25    specific tasks or duties, the collaborating physician
26    routinely provides individually or through delegation to

 

 

SB0218- 12 -LRB103 25028 AMQ 51362 b

1    other persons so that the physician has the experience and
2    ability to collaborate and provide consultation.
3        (2) (Blank). The written collaborative agreement shall
4    be adequate if a physician does each of the following:
5            (A) Participates in the joint formulation and
6        joint approval of orders or guidelines with the
7        physician assistant and he or she periodically reviews
8        such orders and the services provided patients under
9        such orders in accordance with accepted standards of
10        medical practice and physician assistant practice.
11            (B) Provides consultation at least once a month.
12        (3) A copy of the signed, written collaborative
13    agreement must be available to the Department upon request
14    from both the physician assistant and the collaborating
15    physician.
16        (4) A physician assistant shall inform each
17    collaborating physician of all written collaborative
18    agreements he or she has signed and provide a copy of these
19    to any collaborating physician upon request.
20    (b) To prescribe Schedule II, III, IV, or V controlled
21substances under this Section, a physician assistant must
22obtain a mid-level practitioner controlled substances license.
23A collaborating physician may, but is not required to,
24delegate prescriptive authority to a physician assistant as
25part of a written collaborative agreement. This authority may,
26but is not required to, include prescription of, selection of,

 

 

SB0218- 13 -LRB103 25028 AMQ 51362 b

1orders for, administration of, storage of, acceptance of
2samples of, and dispensing medical devices, over the counter
3medications, legend drugs, medical gases, and controlled
4substances categorized as Schedule II through V controlled
5substances, as defined in Article II of the Illinois
6Controlled Substances Act, and other preparations, including,
7but not limited to, botanical and herbal remedies. The
8collaborating physician must have a valid, current Illinois
9controlled substance license and federal registration with the
10Drug Enforcement Administration to delegate the authority to
11prescribe controlled substances.
12        (1) To prescribe Schedule II, III, IV, or V controlled
13    substances under this Section, a physician assistant must
14    obtain a mid-level practitioner controlled substances
15    license. Medication orders issued by a physician assistant
16    shall be reviewed periodically by the collaborating
17    physician.
18        (2) The collaborating physician shall file with the
19    Department notice of delegation of prescriptive authority
20    to a physician assistant and termination of delegation,
21    specifying the authority delegated or terminated. Upon
22    receipt of this notice delegating authority to prescribe
23    controlled substances, the physician assistant shall be
24    eligible to register for a mid-level practitioner
25    controlled substances license under Section 303.05 of the
26    Illinois Controlled Substances Act. Nothing in this Act

 

 

SB0218- 14 -LRB103 25028 AMQ 51362 b

1    shall be construed to limit the delegation of tasks or
2    duties by the collaborating physician to a nurse or other
3    appropriately trained persons in accordance with Section
4    54.2 of the Medical Practice Act of 1987.
5        (3) In addition to the requirements of this subsection
6    (b), a collaborating physician may, but is not required
7    to, delegate authority to a physician assistant to
8    prescribe Schedule II controlled substances, if all of the
9    following conditions apply:
10            (A) Specific Schedule II controlled substances by
11        oral dosage or topical or transdermal application may
12        be delegated, provided that the delegated Schedule II
13        controlled substances are routinely prescribed by the
14        collaborating physician. This delegation must identify
15        the specific Schedule II controlled substances by
16        either brand name or generic name. Schedule II
17        controlled substances to be delivered by injection or
18        other route of administration may not be delegated.
19            (B) (Blank).
20            (C) Any prescription must be limited to no more
21        than a 30-day supply, with any continuation authorized
22        only after prior approval of the collaborating
23        physician.
24            (D) The physician assistant must discuss the
25        condition of any patients for whom a controlled
26        substance is prescribed monthly with the collaborating

 

 

SB0218- 15 -LRB103 25028 AMQ 51362 b

1        physician.
2            (E) The physician assistant meets the education
3        requirements of Section 303.05 of the Illinois
4        Controlled Substances Act.
5    (c) Nothing in this Act shall be construed to limit the
6delegation of tasks or duties by a physician to a licensed
7practical nurse, a registered professional nurse, or other
8persons. Nothing in this Act shall be construed to limit the
9method of delegation that may be authorized by any means,
10including, but not limited to, oral, written, electronic,
11standing orders, protocols, guidelines, or verbal orders.
12Nothing in this Act shall be construed to authorize a
13physician assistant to provide health care services required
14by law or rule to be performed by a physician. Nothing in this
15Act shall be construed to authorize the delegation or
16performance of operative surgery. Nothing in this Section
17shall be construed to preclude a physician assistant from
18assisting in surgery.
19    (c-5) Nothing in this Section shall be construed to apply
20to any medication authority, including Schedule II controlled
21substances of a licensed physician assistant for care provided
22in a hospital, hospital affiliate, or ambulatory surgical
23treatment center pursuant to Section 7.7 of this Act or to a
24physician assistant meeting the requirements of Section 7.9 of
25this Act.
26    (d) (Blank).

 

 

SB0218- 16 -LRB103 25028 AMQ 51362 b

1    (e) Nothing in this Section shall be construed to prohibit
2generic substitution.
3    (f) Delegation of prescriptive authority by a physician is
4not required under this Section.
5(Source: P.A. 101-13, eff. 6-12-19; 102-558, eff. 8-20-21.)
 
6    (225 ILCS 95/7.7)
7    (Section scheduled to be repealed on January 1, 2028)
8    Sec. 7.7. Physician assistants in hospitals, hospital
9affiliates, or ambulatory surgical treatment centers.
10    (a) A physician assistant may provide services in a
11hospital as defined in the Hospital Licensing Act, a hospital
12affiliate as defined in the University of Illinois Hospital
13Act, or a licensed ambulatory surgical treatment center as
14defined in the Ambulatory Surgical Treatment Center Act
15without a written collaborative agreement pursuant to Section
167.5 of this Act. A physician assistant must possess clinical
17privileges recommended by the hospital medical staff and
18granted by the hospital or the consulting medical staff
19committee and ambulatory surgical treatment center in order to
20provide services. The medical staff or consulting medical
21staff committee shall periodically review the services of
22physician assistants granted clinical privileges, including
23any care provided in a hospital affiliate. A physician
24assistant practicing under this Section shall have the
25authority to prescribe, select, order, and administer

 

 

SB0218- 17 -LRB103 25028 AMQ 51362 b

1medications, including controlled substances. Authority may
2also be granted when recommended by the hospital medical staff
3and granted by the hospital or recommended by the consulting
4medical staff committee and ambulatory surgical treatment
5center to individual physician assistants to select, order,
6and administer medications, including controlled substances,
7to provide delineated care. In a hospital, hospital affiliate,
8or ambulatory surgical treatment center, the attending
9physician shall determine a physician assistant's role in
10providing care for his or her patients, except as otherwise
11provided in the medical staff bylaws or consulting committee
12policies.
13    (a-5) Physician assistants practicing in a hospital
14affiliate shall have the authority may be, but are not
15required to be, granted authority to prescribe Schedule II
16through V controlled substances when such authority is
17recommended by the appropriate physician committee of the
18hospital affiliate and granted by the hospital affiliate. This
19authority includes may, but is not required to, include
20prescription of, selection of, orders for, administration of,
21storage of, acceptance of samples of, and dispensing
22over-the-counter medications, legend drugs, medical gases, and
23controlled substances categorized as Schedule II through V
24controlled substances, as defined in Article II of the
25Illinois Controlled Substances Act, and other preparations,
26including, but not limited to, botanical and herbal remedies.

 

 

SB0218- 18 -LRB103 25028 AMQ 51362 b

1    To prescribe controlled substances under this subsection
2(a-5), a physician assistant must obtain a mid-level
3practitioner controlled substance license. Medication orders
4shall be reviewed periodically by the appropriate hospital
5affiliate physicians committee or its physician designee.
6    The hospital affiliate shall file with the Department
7notice of a grant of prescriptive authority consistent with
8this subsection (a-5) and termination of such a grant of
9authority in accordance with rules of the Department. Upon
10receipt of this notice of grant of authority to prescribe any
11Schedule II through V controlled substances, the licensed
12physician assistant may register for a mid-level practitioner
13controlled substance license under Section 303.05 of the
14Illinois Controlled Substances Act.
15    In addition, a hospital affiliate may, but is not required
16to, grant authority to a physician assistant to prescribe any
17Schedule II controlled substances if all of the following
18conditions apply:
19        (1) specific Schedule II controlled substances by oral
20    dosage or topical or transdermal application may be
21    designated, provided that the designated Schedule II
22    controlled substances are routinely prescribed by
23    physician assistants in their area of certification; this
24    grant of authority must identify the specific Schedule II
25    controlled substances by either brand name or generic
26    name; authority to prescribe or dispense Schedule II

 

 

SB0218- 19 -LRB103 25028 AMQ 51362 b

1    controlled substances to be delivered by injection or
2    other route of administration may not be granted;
3        (2) any grant of authority must be controlled
4    substances limited to the practice of the physician
5    assistant;
6        (3) any prescription must be limited to no more than a
7    30-day supply;
8        (4) the physician assistant must discuss the condition
9    of any patients for whom a controlled substance is
10    prescribed monthly with the appropriate physician
11    committee of the hospital affiliate or its physician
12    designee; and
13        (5) the physician assistant must meet the education
14    requirements of Section 303.05 of the Illinois Controlled
15    Substances Act.
16    (b) A physician assistant granted authority to order
17medications including controlled substances may complete
18discharge prescriptions provided the prescription is in the
19name of the physician assistant and the attending or
20discharging physician.
21    (c) Physician assistants practicing in a hospital,
22hospital affiliate, or an ambulatory surgical treatment center
23are not required to obtain a mid-level controlled substance
24license to order controlled substances under Section 303.05 of
25the Illinois Controlled Substances Act.
26    (d) Delegation of prescriptive authority by a physician is

 

 

SB0218- 20 -LRB103 25028 AMQ 51362 b

1not required under this Section.
2(Source: P.A. 100-453, eff. 8-25-17.)
 
3    (225 ILCS 95/7.8 new)
4    Sec. 7.8. Prescriptive authority. A physician assistant
5shall be deemed by law to possess the ability to prescribe,
6dispense, order, administer, and procure drugs and medical
7devices without delegation of such authority by a physician.
8Such ability shall include prescribing Schedule II, III, IV,
9and V controlled substances. To prescribe Schedule II, III,
10IV, or V controlled substances under this Act, a physician
11assistant shall obtain a mid-level practitioner controlled
12substances license. When a written collaborative agreement is
13required under this Act, delegation of prescriptive authority
14by a physician is not required.
 
15    (225 ILCS 95/7.9 new)
16    Sec. 7.9. Optimal practice authority.
17    (a) A physician assistant shall be deemed by law to
18possess the ability to practice without a written
19collaborative agreement as set forth in this Section.
20    (b) A physician assistant who files with the Department a
21notarized attestation of completion of at least 250 hours of
22continuing education or training and at least 2,000 hours of
23clinical experience after first attaining national
24certification shall not require a written collaborative

 

 

SB0218- 21 -LRB103 25028 AMQ 51362 b

1agreement. Documentation of successful completion shall be
2provided to the Department upon request.
3    (c) The scope of practice of a physician assistant with
4optimal practice authority includes:
5        (1) all matters included in subsection (3.5) of
6    Section 4;
7        (2) practicing without a written collaborative
8    agreement in all practice settings consistent with this
9    Act;
10        (3) authority to prescribe both legend drugs and
11    Schedule II through V controlled substances; this
12    authority includes prescription of, selection of, orders
13    for, administration of, storage of, acceptance of samples
14    of, and dispensing over-the-counter medications, legend
15    drugs, and controlled substances categorized as any
16    Schedule II through V controlled substances, as defined in
17    Article II of the Illinois Controlled Substances Act, and
18    other preparations, including, but not limited to,
19    botanical and herbal remedies; and
20        (4) authority to obtain a controlled substances
21    license in the State and a federal Drug Enforcement
22    Administration number.
23    The scope of practice of a physician assistant does not
24include operative surgery. Nothing in this Section shall be
25construed to preclude a physician assistant from assisting in
26surgery or performing other procedures as privileged by the

 

 

SB0218- 22 -LRB103 25028 AMQ 51362 b

1physician assistant's employer.
2    (d) The Department may adopt rules necessary to administer
3this Section, including, but not limited to, requiring the
4completion of forms and the payment of fees.
5    (e) Nothing in this Act shall be construed to authorize a
6physician assistant with optimal practice authority to provide
7health care services required by law or rule to be performed by
8a physician.
 
9    (225 ILCS 95/17)  (from Ch. 111, par. 4617)
10    (Section scheduled to be repealed on January 1, 2028)
11    Sec. 17. Inactive status. Any physician assistant who
12notified the Department in writing on forms prescribed by the
13Department, may elect to place his or her license on an
14inactive status and shall, subject to rules of the Department,
15be excused from payment of renewal fees until he or she
16notifies the Department in writing of his or her intention to
17restore the license. Any person who holds an active license or
18permit issued pursuant to the Medical Practice Act of 1987
19shall have that license automatically placed into inactive
20status upon issuance of a physician assistant license. Any
21person who holds an active license as a physician assistant
22who is issued a license or permit pursuant to the Medical
23Practice Act of 1987 shall have the physician assistant
24license automatically placed into inactive status.
25    Any physician assistant requesting restoration from

 

 

SB0218- 23 -LRB103 25028 AMQ 51362 b

1inactive status shall be required to pay the current renewal
2fee and shall be required to restore his or her license, as
3provided in Section 16 of this Act.
4    Any physician assistant whose license is in an inactive
5status shall not practice in the State of Illinois.
6    Any licensee who shall engage in practice while his or her
7license is lapsed or on inactive status shall be considered to
8be practicing without a license, which shall be grounds for
9discipline under Section 21 of this Act.
10(Source: P.A. 90-61, eff. 12-30-97.)
 
11    (225 ILCS 95/21)  (from Ch. 111, par. 4621)
12    (Section scheduled to be repealed on January 1, 2028)
13    Sec. 21. Grounds for disciplinary action.
14    (a) The Department may refuse to issue or to renew, or may
15revoke, suspend, place on probation, reprimand, or take other
16disciplinary or non-disciplinary action with regard to any
17license issued under this Act as the Department may deem
18proper, including the issuance of fines not to exceed $10,000
19for each violation, for any one or combination of the
20following causes:
21        (1) Material misstatement in furnishing information to
22    the Department.
23        (2) Violations of this Act, or the rules adopted under
24    this Act.
25        (3) Conviction by plea of guilty or nolo contendere,

 

 

SB0218- 24 -LRB103 25028 AMQ 51362 b

1    finding of guilt, jury verdict, or entry of judgment or
2    sentencing, including, but not limited to, convictions,
3    preceding sentences of supervision, conditional discharge,
4    or first offender probation, under the laws of any
5    jurisdiction of the United States that is: (i) a felony;
6    or (ii) a misdemeanor, an essential element of which is
7    dishonesty, or that is directly related to the practice of
8    the profession.
9        (4) Making any misrepresentation for the purpose of
10    obtaining licenses.
11        (5) Professional incompetence.
12        (6) Aiding or assisting another person in violating
13    any provision of this Act or its rules.
14        (7) Failing, within 60 days, to provide information in
15    response to a written request made by the Department.
16        (8) Engaging in dishonorable, unethical, or
17    unprofessional conduct, as defined by rule, of a character
18    likely to deceive, defraud, or harm the public.
19        (9) Habitual or excessive use or addiction to alcohol,
20    narcotics, stimulants, or any other chemical agent or drug
21    that results in a physician assistant's inability to
22    practice with reasonable judgment, skill, or safety.
23        (10) Discipline by another U.S. jurisdiction or
24    foreign nation, if at least one of the grounds for
25    discipline is the same or substantially equivalent to
26    those set forth in this Section.

 

 

SB0218- 25 -LRB103 25028 AMQ 51362 b

1        (11) Directly or indirectly giving to or receiving
2    from any person, firm, corporation, partnership, or
3    association any fee, commission, rebate or other form of
4    compensation for any professional services not actually or
5    personally rendered. Nothing in this paragraph (11)
6    affects any bona fide independent contractor or employment
7    arrangements, which may include provisions for
8    compensation, health insurance, pension, or other
9    employment benefits, with persons or entities authorized
10    under this Act for the provision of services within the
11    scope of the licensee's practice under this Act.
12        (12) A finding by the Board that the licensee, after
13    having his or her license placed on probationary status,
14    has violated the terms of probation.
15        (13) Abandonment of a patient.
16        (14) Willfully making or filing false records or
17    reports in his or her practice, including but not limited
18    to false records filed with State agencies or departments.
19        (15) Willfully failing to report an instance of
20    suspected child abuse or neglect as required by the Abused
21    and Neglected Child Reporting Act.
22        (16) Physical illness, or mental illness or impairment
23    that results in the inability to practice the profession
24    with reasonable judgment, skill, or safety, including, but
25    not limited to, deterioration through the aging process or
26    loss of motor skill.

 

 

SB0218- 26 -LRB103 25028 AMQ 51362 b

1        (17) Being named as a perpetrator in an indicated
2    report by the Department of Children and Family Services
3    under the Abused and Neglected Child Reporting Act, and
4    upon proof by clear and convincing evidence that the
5    licensee has caused a child to be an abused child or
6    neglected child as defined in the Abused and Neglected
7    Child Reporting Act.
8        (18) (Blank).
9        (19) Gross negligence resulting in permanent injury or
10    death of a patient.
11        (20) Employment of fraud, deception or any unlawful
12    means in applying for or securing a license as a physician
13    assistant.
14        (21) Exceeding the authority delegated to him or her
15    by his or her collaborating physician in a written
16    collaborative agreement when such agreement is required
17    under this Act.
18        (22) Immoral conduct in the commission of any act,
19    such as sexual abuse, sexual misconduct, or sexual
20    exploitation related to the licensee's practice.
21        (23) Violation of the Health Care Worker Self-Referral
22    Act.
23        (24) Practicing under a false or assumed name, except
24    as provided by law.
25        (25) Making a false or misleading statement regarding
26    his or her skill or the efficacy or value of the medicine,

 

 

SB0218- 27 -LRB103 25028 AMQ 51362 b

1    treatment, or remedy prescribed by him or her in the
2    course of treatment.
3        (26) Allowing another person to use his or her license
4    to practice.
5        (27) Prescribing, selling, administering,
6    distributing, giving, or self-administering a drug
7    classified as a controlled substance for other than
8    medically accepted therapeutic purposes.
9        (28) Promotion of the sale of drugs, devices,
10    appliances, or goods provided for a patient in a manner to
11    exploit the patient for financial gain.
12        (29) A pattern of practice or other behavior that
13    demonstrates incapacity or incompetence to practice under
14    this Act.
15        (30) Violating State or federal laws or regulations
16    relating to controlled substances or other legend drugs or
17    ephedra as defined in the Ephedra Prohibition Act.
18        (31) (Blank). Exceeding the prescriptive authority
19    delegated by the collaborating physician or violating the
20    written collaborative agreement delegating that authority.
21        (32) (Blank). Practicing without providing to the
22    Department a notice of collaboration or delegation of
23    prescriptive authority.
24        (33) Failure to establish and maintain records of
25    patient care and treatment as required by law.
26        (34) Attempting to subvert or cheat on the examination

 

 

SB0218- 28 -LRB103 25028 AMQ 51362 b

1    of the National Commission on Certification of Physician
2    Assistants or its successor agency.
3        (35) Willfully or negligently violating the
4    confidentiality between physician assistant and patient,
5    except as required by law.
6        (36) Willfully failing to report an instance of
7    suspected abuse, neglect, financial exploitation, or
8    self-neglect of an eligible adult as defined in and
9    required by the Adult Protective Services Act.
10        (37) Being named as an abuser in a verified report by
11    the Department on Aging under the Adult Protective
12    Services Act and upon proof by clear and convincing
13    evidence that the licensee abused, neglected, or
14    financially exploited an eligible adult as defined in the
15    Adult Protective Services Act.
16        (38) Failure to report to the Department an adverse
17    final action taken against him or her by another licensing
18    jurisdiction of the United States or a foreign state or
19    country, a peer review body, a health care institution, a
20    professional society or association, a governmental
21    agency, a law enforcement agency, or a court acts or
22    conduct similar to acts or conduct that would constitute
23    grounds for action under this Section.
24        (39) Failure to provide copies of records of patient
25    care or treatment, except as required by law.
26        (40) When a written collaborative agreement is

 

 

SB0218- 29 -LRB103 25028 AMQ 51362 b

1    required under this Act, entering Entering into an
2    excessive number of written collaborative agreements with
3    licensed physicians resulting in an inability to
4    adequately collaborate.
5        (41) When a written collaborative agreement is
6    required under this Act, repeated Repeated failure to
7    adequately collaborate with a collaborating physician.
8        (42) Violating the Compassionate Use of Medical
9    Cannabis Program Act.
10    (b) The Department may, without a hearing, refuse to issue
11or renew or may suspend the license of any person who fails to
12file a return, or to pay the tax, penalty or interest shown in
13a filed return, or to pay any final assessment of the tax,
14penalty, or interest as required by any tax Act administered
15by the Illinois Department of Revenue, until such time as the
16requirements of any such tax Act are satisfied.
17    (b-5) The Department shall not revoke, suspend, summarily
18suspend, place on prohibition, reprimand, refuse to issue or
19renew, or take any other disciplinary or non-disciplinary
20action against the license or permit issued under this Act to
21practice as a physician assistant based solely upon the
22physician assistant providing, authorizing, recommending,
23aiding, assisting, referring for, or otherwise participating
24in any health care service, so long as the care was not
25unlawful under the laws of this State, regardless of whether
26the patient was a resident of this State or another state.

 

 

SB0218- 30 -LRB103 25028 AMQ 51362 b

1    (b-10) The Department shall not revoke, suspend, summarily
2suspend, place on prohibition, reprimand, refuse to issue or
3renew, or take any other disciplinary or non-disciplinary
4action against the license or permit issued under this Act to
5practice as a physician assistant based upon the physician
6assistant's license being revoked or suspended, or the
7physician assistant being otherwise disciplined by any other
8state, if that revocation, suspension, or other form of
9discipline was based solely on the physician assistant
10violating another state's laws prohibiting the provision of,
11authorization of, recommendation of, aiding or assisting in,
12referring for, or participation in any health care service if
13that health care service as provided would not have been
14unlawful under the laws of this State and is consistent with
15the standards of conduct for a physician assistant practicing
16in Illinois.
17    (b-15) The conduct specified in subsections (b-5) and
18(b-10) shall not constitute grounds for suspension under
19Section 22.13.
20    (b-20) An applicant seeking licensure, certification, or
21authorization pursuant to this Act who has been subject to
22disciplinary action by a duly authorized professional
23disciplinary agency of another jurisdiction solely on the
24basis of having provided, authorized, recommended, aided,
25assisted, referred for, or otherwise participated in health
26care shall not be denied such licensure, certification, or

 

 

SB0218- 31 -LRB103 25028 AMQ 51362 b

1authorization, unless the Department determines that such
2action would have constituted professional misconduct in this
3State; however, nothing in this Section shall be construed as
4prohibiting the Department from evaluating the conduct of such
5applicant and making a determination regarding the licensure,
6certification, or authorization to practice a profession under
7this Act.
8    (c) The determination by a circuit court that a licensee
9is subject to involuntary admission or judicial admission as
10provided in the Mental Health and Developmental Disabilities
11Code operates as an automatic suspension. The suspension will
12end only upon a finding by a court that the patient is no
13longer subject to involuntary admission or judicial admission
14and issues an order so finding and discharging the patient,
15and upon the recommendation of the Board to the Secretary that
16the licensee be allowed to resume his or her practice.
17    (d) In enforcing this Section, the Department upon a
18showing of a possible violation may compel an individual
19licensed to practice under this Act, or who has applied for
20licensure under this Act, to submit to a mental or physical
21examination, or both, which may include a substance abuse or
22sexual offender evaluation, as required by and at the expense
23of the Department.
24    The Department shall specifically designate the examining
25physician licensed to practice medicine in all of its branches
26or, if applicable, the multidisciplinary team involved in

 

 

SB0218- 32 -LRB103 25028 AMQ 51362 b

1providing the mental or physical examination or both. The
2multidisciplinary team shall be led by a physician licensed to
3practice medicine in all of its branches and may consist of one
4or more or a combination of physicians licensed to practice
5medicine in all of its branches, licensed clinical
6psychologists, licensed clinical social workers, licensed
7clinical professional counselors, and other professional and
8administrative staff. Any examining physician or member of the
9multidisciplinary team may require any person ordered to
10submit to an examination pursuant to this Section to submit to
11any additional supplemental testing deemed necessary to
12complete any examination or evaluation process, including, but
13not limited to, blood testing, urinalysis, psychological
14testing, or neuropsychological testing.
15    The Department may order the examining physician or any
16member of the multidisciplinary team to provide to the
17Department any and all records, including business records,
18that relate to the examination and evaluation, including any
19supplemental testing performed.
20    The Department may order the examining physician or any
21member of the multidisciplinary team to present testimony
22concerning the mental or physical examination of the licensee
23or applicant. No information, report, record, or other
24documents in any way related to the examination shall be
25excluded by reason of any common law or statutory privilege
26relating to communications between the licensee or applicant

 

 

SB0218- 33 -LRB103 25028 AMQ 51362 b

1and the examining physician or any member of the
2multidisciplinary team. No authorization is necessary from the
3licensee or applicant ordered to undergo an examination for
4the examining physician or any member of the multidisciplinary
5team to provide information, reports, records, or other
6documents or to provide any testimony regarding the
7examination and evaluation.
8    The individual to be examined may have, at his or her own
9expense, another physician of his or her choice present during
10all aspects of this examination. However, that physician shall
11be present only to observe and may not interfere in any way
12with the examination.
13     Failure of an individual to submit to a mental or physical
14examination, when ordered, shall result in an automatic
15suspension of his or her license until the individual submits
16to the examination.
17    If the Department finds an individual unable to practice
18because of the reasons set forth in this Section, the
19Department may require that individual to submit to care,
20counseling, or treatment by physicians approved or designated
21by the Department, as a condition, term, or restriction for
22continued, reinstated, or renewed licensure to practice; or,
23in lieu of care, counseling, or treatment, the Department may
24file a complaint to immediately suspend, revoke, or otherwise
25discipline the license of the individual. An individual whose
26license was granted, continued, reinstated, renewed,

 

 

SB0218- 34 -LRB103 25028 AMQ 51362 b

1disciplined, or supervised subject to such terms, conditions,
2or restrictions, and who fails to comply with such terms,
3conditions, or restrictions, shall be referred to the
4Secretary for a determination as to whether the individual
5shall have his or her license suspended immediately, pending a
6hearing by the Department.
7    In instances in which the Secretary immediately suspends a
8person's license under this Section, a hearing on that
9person's license must be convened by the Department within 30
10days after the suspension and completed without appreciable
11delay. The Department shall have the authority to review the
12subject individual's record of treatment and counseling
13regarding the impairment to the extent permitted by applicable
14federal statutes and regulations safeguarding the
15confidentiality of medical records.
16    An individual licensed under this Act and affected under
17this Section shall be afforded an opportunity to demonstrate
18to the Department that he or she can resume practice in
19compliance with acceptable and prevailing standards under the
20provisions of his or her license.
21    (e) An individual or organization acting in good faith,
22and not in a willful and wanton manner, in complying with this
23Section by providing a report or other information to the
24Board, by assisting in the investigation or preparation of a
25report or information, by participating in proceedings of the
26Board, or by serving as a member of the Board, shall not be

 

 

SB0218- 35 -LRB103 25028 AMQ 51362 b

1subject to criminal prosecution or civil damages as a result
2of such actions.
3    (f) Members of the Board shall be indemnified by the State
4for any actions occurring within the scope of services on the
5Board, done in good faith and not willful and wanton in nature.
6The Attorney General shall defend all such actions unless he
7or she determines either that there would be a conflict of
8interest in such representation or that the actions complained
9of were not in good faith or were willful and wanton.
10    If the Attorney General declines representation, the
11member has the right to employ counsel of his or her choice,
12whose fees shall be provided by the State, after approval by
13the Attorney General, unless there is a determination by a
14court that the member's actions were not in good faith or were
15willful and wanton.
16    The member must notify the Attorney General within 7 days
17after receipt of notice of the initiation of any action
18involving services of the Board. Failure to so notify the
19Attorney General constitutes an absolute waiver of the right
20to a defense and indemnification.
21    The Attorney General shall determine, within 7 days after
22receiving such notice, whether he or she will undertake to
23represent the member.
24    (g) The Department may adopt rules to implement the
25changes made by this amendatory Act of the 102nd General
26Assembly.

 

 

SB0218- 36 -LRB103 25028 AMQ 51362 b

1(Source: P.A. 101-363, eff. 8-9-19; 102-558, eff. 8-20-21;
2102-1117, eff. 1-13-23.)
 
3    Section 10. The Illinois Controlled Substances Act is
4amended by changing Sections 102 and 303.05 as follows:
 
5    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
6    Sec. 102. Definitions. As used in this Act, unless the
7context otherwise requires:
8    (a) "Addict" means any person who habitually uses any
9drug, chemical, substance or dangerous drug other than alcohol
10so as to endanger the public morals, health, safety or welfare
11or who is so far addicted to the use of a dangerous drug or
12controlled substance other than alcohol as to have lost the
13power of self control with reference to his or her addiction.
14    (b) "Administer" means the direct application of a
15controlled substance, whether by injection, inhalation,
16ingestion, or any other means, to the body of a patient,
17research subject, or animal (as defined by the Humane
18Euthanasia in Animal Shelters Act) by:
19        (1) a practitioner (or, in his or her presence, by his
20    or her authorized agent),
21        (2) the patient or research subject pursuant to an
22    order, or
23        (3) a euthanasia technician as defined by the Humane
24    Euthanasia in Animal Shelters Act.

 

 

SB0218- 37 -LRB103 25028 AMQ 51362 b

1    (c) "Agent" means an authorized person who acts on behalf
2of or at the direction of a manufacturer, distributor,
3dispenser, prescriber, or practitioner. It does not include a
4common or contract carrier, public warehouseman or employee of
5the carrier or warehouseman.
6    (c-1) "Anabolic Steroids" means any drug or hormonal
7substance, chemically and pharmacologically related to
8testosterone (other than estrogens, progestins,
9corticosteroids, and dehydroepiandrosterone), and includes:
10    (i) 3[beta],17-dihydroxy-5a-androstane, 
11    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
12    (iii) 5[alpha]-androstan-3,17-dione, 
13    (iv) 1-androstenediol (3[beta], 
14        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
15    (v) 1-androstenediol (3[alpha], 
16        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
17    (vi) 4-androstenediol  
18        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
19    (vii) 5-androstenediol  
20        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
21    (viii) 1-androstenedione  
22        ([5alpha]-androst-1-en-3,17-dione), 
23    (ix) 4-androstenedione  
24        (androst-4-en-3,17-dione), 
25    (x) 5-androstenedione  
26        (androst-5-en-3,17-dione), 

 

 

SB0218- 38 -LRB103 25028 AMQ 51362 b

1    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
2        hydroxyandrost-4-en-3-one), 
3    (xii) boldenone (17[beta]-hydroxyandrost- 
4        1,4,-diene-3-one), 
5    (xiii) boldione (androsta-1,4- 
6        diene-3,17-dione), 
7    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
8        [beta]-hydroxyandrost-4-en-3-one), 
9    (xv) clostebol (4-chloro-17[beta]- 
10        hydroxyandrost-4-en-3-one), 
11    (xvi) dehydrochloromethyltestosterone (4-chloro- 
12        17[beta]-hydroxy-17[alpha]-methyl- 
13        androst-1,4-dien-3-one), 
14    (xvii) desoxymethyltestosterone 
15    (17[alpha]-methyl-5[alpha] 
16        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
17    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
18        '1-testosterone') (17[beta]-hydroxy- 
19        5[alpha]-androst-1-en-3-one), 
20    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
21        androstan-3-one), 
22    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
23        5[alpha]-androstan-3-one), 
24    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
25        hydroxyestr-4-ene), 
26    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 

 

 

SB0218- 39 -LRB103 25028 AMQ 51362 b

1        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
2    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
3        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
4    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
5        hydroxyandrostano[2,3-c]-furazan), 
6    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, 
7    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
8        androst-4-en-3-one), 
9    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
10        dihydroxy-estr-4-en-3-one), 
11    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
12        hydroxy-5-androstan-3-one), 
13    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
14        [5a]-androstan-3-one), 
15    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
16        hydroxyandrost-1,4-dien-3-one), 
17    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
18        dihydroxyandrost-5-ene), 
19    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
20        5[alpha]-androst-1-en-3-one), 
21    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
22        dihydroxy-5a-androstane, 
23    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
24        -5a-androstane, 
25    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
26        dihydroxyandrost-4-ene), 

 

 

SB0218- 40 -LRB103 25028 AMQ 51362 b

1    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
2        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
3    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
4        hydroxyestra-4,9(10)-dien-3-one), 
5    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
6        hydroxyestra-4,9-11-trien-3-one), 
7    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
8        hydroxyandrost-4-en-3-one), 
9    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
10        hydroxyestr-4-en-3-one), 
11    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
12        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
13        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
14        1-testosterone'), 
15    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
16    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
17        dihydroxyestr-4-ene), 
18    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
19        dihydroxyestr-4-ene), 
20    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
21        dihydroxyestr-5-ene), 
22    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
23        dihydroxyestr-5-ene), 
24    (xlvii) 19-nor-4,9(10)-androstadienedione  
25        (estra-4,9(10)-diene-3,17-dione), 
26    (xlviii) 19-nor-4-androstenedione (estr-4- 

 

 

SB0218- 41 -LRB103 25028 AMQ 51362 b

1        en-3,17-dione), 
2    (xlix) 19-nor-5-androstenedione (estr-5- 
3        en-3,17-dione), 
4    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
5        hydroxygon-4-en-3-one), 
6    (li) norclostebol (4-chloro-17[beta]- 
7        hydroxyestr-4-en-3-one), 
8    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
9        hydroxyestr-4-en-3-one), 
10    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
11        hydroxyestr-4-en-3-one), 
12    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
13        2-oxa-5[alpha]-androstan-3-one), 
14    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
15        dihydroxyandrost-4-en-3-one), 
16    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
17        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
18    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
19        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
20    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
21        (5[alpha]-androst-1-en-3-one), 
22    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
23        secoandrosta-1,4-dien-17-oic 
24        acid lactone), 
25    (lx) testosterone (17[beta]-hydroxyandrost- 
26        4-en-3-one), 

 

 

SB0218- 42 -LRB103 25028 AMQ 51362 b

1    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
2        diethyl-17[beta]-hydroxygon- 
3        4,9,11-trien-3-one), 
4    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
5        11-trien-3-one). 
6    Any person who is otherwise lawfully in possession of an
7anabolic steroid, or who otherwise lawfully manufactures,
8distributes, dispenses, delivers, or possesses with intent to
9deliver an anabolic steroid, which anabolic steroid is
10expressly intended for and lawfully allowed to be administered
11through implants to livestock or other nonhuman species, and
12which is approved by the Secretary of Health and Human
13Services for such administration, and which the person intends
14to administer or have administered through such implants,
15shall not be considered to be in unauthorized possession or to
16unlawfully manufacture, distribute, dispense, deliver, or
17possess with intent to deliver such anabolic steroid for
18purposes of this Act.
19    (d) "Administration" means the Drug Enforcement
20Administration, United States Department of Justice, or its
21successor agency.
22    (d-5) "Clinical Director, Prescription Monitoring Program"
23means a Department of Human Services administrative employee
24licensed to either prescribe or dispense controlled substances
25who shall run the clinical aspects of the Department of Human
26Services Prescription Monitoring Program and its Prescription

 

 

SB0218- 43 -LRB103 25028 AMQ 51362 b

1Information Library.
2    (d-10) "Compounding" means the preparation and mixing of
3components, excluding flavorings, (1) as the result of a
4prescriber's prescription drug order or initiative based on
5the prescriber-patient-pharmacist relationship in the course
6of professional practice or (2) for the purpose of, or
7incident to, research, teaching, or chemical analysis and not
8for sale or dispensing. "Compounding" includes the preparation
9of drugs or devices in anticipation of receiving prescription
10drug orders based on routine, regularly observed dispensing
11patterns. Commercially available products may be compounded
12for dispensing to individual patients only if both of the
13following conditions are met: (i) the commercial product is
14not reasonably available from normal distribution channels in
15a timely manner to meet the patient's needs and (ii) the
16prescribing practitioner has requested that the drug be
17compounded.
18    (e) "Control" means to add a drug or other substance, or
19immediate precursor, to a Schedule whether by transfer from
20another Schedule or otherwise.
21    (f) "Controlled Substance" means (i) a drug, substance,
22immediate precursor, or synthetic drug in the Schedules of
23Article II of this Act or (ii) a drug or other substance, or
24immediate precursor, designated as a controlled substance by
25the Department through administrative rule. The term does not
26include distilled spirits, wine, malt beverages, or tobacco,

 

 

SB0218- 44 -LRB103 25028 AMQ 51362 b

1as those terms are defined or used in the Liquor Control Act of
21934 and the Tobacco Products Tax Act of 1995.
3    (f-5) "Controlled substance analog" means a substance:
4        (1) the chemical structure of which is substantially
5    similar to the chemical structure of a controlled
6    substance in Schedule I or II;
7        (2) which has a stimulant, depressant, or
8    hallucinogenic effect on the central nervous system that
9    is substantially similar to or greater than the stimulant,
10    depressant, or hallucinogenic effect on the central
11    nervous system of a controlled substance in Schedule I or
12    II; or
13        (3) with respect to a particular person, which such
14    person represents or intends to have a stimulant,
15    depressant, or hallucinogenic effect on the central
16    nervous system that is substantially similar to or greater
17    than the stimulant, depressant, or hallucinogenic effect
18    on the central nervous system of a controlled substance in
19    Schedule I or II.
20    (g) "Counterfeit substance" means a controlled substance,
21which, or the container or labeling of which, without
22authorization bears the trademark, trade name, or other
23identifying mark, imprint, number or device, or any likeness
24thereof, of a manufacturer, distributor, or dispenser other
25than the person who in fact manufactured, distributed, or
26dispensed the substance.

 

 

SB0218- 45 -LRB103 25028 AMQ 51362 b

1    (h) "Deliver" or "delivery" means the actual, constructive
2or attempted transfer of possession of a controlled substance,
3with or without consideration, whether or not there is an
4agency relationship. "Deliver" or "delivery" does not include
5the donation of drugs to the extent permitted under the
6Illinois Drug Reuse Opportunity Program Act.
7    (i) "Department" means the Illinois Department of Human
8Services (as successor to the Department of Alcoholism and
9Substance Abuse) or its successor agency.
10    (j) (Blank).
11    (k) "Department of Corrections" means the Department of
12Corrections of the State of Illinois or its successor agency.
13    (l) "Department of Financial and Professional Regulation"
14means the Department of Financial and Professional Regulation
15of the State of Illinois or its successor agency.
16    (m) "Depressant" means any drug that (i) causes an overall
17depression of central nervous system functions, (ii) causes
18impaired consciousness and awareness, and (iii) can be
19habit-forming or lead to a substance abuse problem, including,
20but not limited to, alcohol, cannabis and its active
21principles and their analogs, benzodiazepines and their
22analogs, barbiturates and their analogs, opioids (natural and
23synthetic) and their analogs, and chloral hydrate and similar
24sedative hypnotics.
25    (n) (Blank).
26    (o) "Director" means the Director of the Illinois State

 

 

SB0218- 46 -LRB103 25028 AMQ 51362 b

1Police or his or her designated agents.
2    (p) "Dispense" means to deliver a controlled substance to
3an ultimate user or research subject by or pursuant to the
4lawful order of a prescriber, including the prescribing,
5administering, packaging, labeling, or compounding necessary
6to prepare the substance for that delivery.
7    (q) "Dispenser" means a practitioner who dispenses.
8    (r) "Distribute" means to deliver, other than by
9administering or dispensing, a controlled substance.
10    (s) "Distributor" means a person who distributes.
11    (t) "Drug" means (1) substances recognized as drugs in the
12official United States Pharmacopoeia, Official Homeopathic
13Pharmacopoeia of the United States, or official National
14Formulary, or any supplement to any of them; (2) substances
15intended for use in diagnosis, cure, mitigation, treatment, or
16prevention of disease in man or animals; (3) substances (other
17than food) intended to affect the structure of any function of
18the body of man or animals and (4) substances intended for use
19as a component of any article specified in clause (1), (2), or
20(3) of this subsection. It does not include devices or their
21components, parts, or accessories.
22    (t-3) "Electronic health record" or "EHR" means an
23electronic record of health-related information on an
24individual that is created, gathered, managed, and consulted
25by authorized health care clinicians and staff.
26    (t-3.5) "Electronic health record system" or "EHR system"

 

 

SB0218- 47 -LRB103 25028 AMQ 51362 b

1means any computer-based system or combination of federally
2certified Health IT Modules (defined at 42 CFR 170.102 or its
3successor) used as a repository for electronic health records
4and accessed or updated by a prescriber or authorized
5surrogate in the ordinary course of his or her medical
6practice. For purposes of connecting to the Prescription
7Information Library maintained by the Bureau of Pharmacy and
8Clinical Support Systems or its successor, an EHR system may
9connect to the Prescription Information Library directly or
10through all or part of a computer program or system that is a
11federally certified Health IT Module maintained by a third
12party and used by the EHR system to secure access to the
13database.
14    (t-4) "Emergency medical services personnel" has the
15meaning ascribed to it in the Emergency Medical Services (EMS)
16Systems Act.
17    (t-5) "Euthanasia agency" means an entity certified by the
18Department of Financial and Professional Regulation for the
19purpose of animal euthanasia that holds an animal control
20facility license or animal shelter license under the Animal
21Welfare Act. A euthanasia agency is authorized to purchase,
22store, possess, and utilize Schedule II nonnarcotic and
23Schedule III nonnarcotic drugs for the sole purpose of animal
24euthanasia.
25    (t-10) "Euthanasia drugs" means Schedule II or Schedule
26III substances (nonnarcotic controlled substances) that are

 

 

SB0218- 48 -LRB103 25028 AMQ 51362 b

1used by a euthanasia agency for the purpose of animal
2euthanasia.
3    (u) "Good faith" means the prescribing or dispensing of a
4controlled substance by a practitioner in the regular course
5of professional treatment to or for any person who is under his
6or her treatment for a pathology or condition other than that
7individual's physical or psychological dependence upon or
8addiction to a controlled substance, except as provided
9herein: and application of the term to a pharmacist shall mean
10the dispensing of a controlled substance pursuant to the
11prescriber's order which in the professional judgment of the
12pharmacist is lawful. The pharmacist shall be guided by
13accepted professional standards, including, but not limited
14to, the following, in making the judgment:
15        (1) lack of consistency of prescriber-patient
16    relationship,
17        (2) frequency of prescriptions for same drug by one
18    prescriber for large numbers of patients,
19        (3) quantities beyond those normally prescribed,
20        (4) unusual dosages (recognizing that there may be
21    clinical circumstances where more or less than the usual
22    dose may be used legitimately),
23        (5) unusual geographic distances between patient,
24    pharmacist and prescriber,
25        (6) consistent prescribing of habit-forming drugs.
26    (u-0.5) "Hallucinogen" means a drug that causes markedly

 

 

SB0218- 49 -LRB103 25028 AMQ 51362 b

1altered sensory perception leading to hallucinations of any
2type.
3    (u-1) "Home infusion services" means services provided by
4a pharmacy in compounding solutions for direct administration
5to a patient in a private residence, long-term care facility,
6or hospice setting by means of parenteral, intravenous,
7intramuscular, subcutaneous, or intraspinal infusion.
8    (u-5) "Illinois State Police" means the Illinois State
9Police or its successor agency.
10    (v) "Immediate precursor" means a substance:
11        (1) which the Department has found to be and by rule
12    designated as being a principal compound used, or produced
13    primarily for use, in the manufacture of a controlled
14    substance;
15        (2) which is an immediate chemical intermediary used
16    or likely to be used in the manufacture of such controlled
17    substance; and
18        (3) the control of which is necessary to prevent,
19    curtail or limit the manufacture of such controlled
20    substance.
21    (w) "Instructional activities" means the acts of teaching,
22educating or instructing by practitioners using controlled
23substances within educational facilities approved by the State
24Board of Education or its successor agency.
25    (x) "Local authorities" means a duly organized State,
26County or Municipal peace unit or police force.

 

 

SB0218- 50 -LRB103 25028 AMQ 51362 b

1    (y) "Look-alike substance" means a substance, other than a
2controlled substance which (1) by overall dosage unit
3appearance, including shape, color, size, markings or lack
4thereof, taste, consistency, or any other identifying physical
5characteristic of the substance, would lead a reasonable
6person to believe that the substance is a controlled
7substance, or (2) is expressly or impliedly represented to be
8a controlled substance or is distributed under circumstances
9which would lead a reasonable person to believe that the
10substance is a controlled substance. For the purpose of
11determining whether the representations made or the
12circumstances of the distribution would lead a reasonable
13person to believe the substance to be a controlled substance
14under this clause (2) of subsection (y), the court or other
15authority may consider the following factors in addition to
16any other factor that may be relevant:
17        (a) statements made by the owner or person in control
18    of the substance concerning its nature, use or effect;
19        (b) statements made to the buyer or recipient that the
20    substance may be resold for profit;
21        (c) whether the substance is packaged in a manner
22    normally used for the illegal distribution of controlled
23    substances;
24        (d) whether the distribution or attempted distribution
25    included an exchange of or demand for money or other
26    property as consideration, and whether the amount of the

 

 

SB0218- 51 -LRB103 25028 AMQ 51362 b

1    consideration was substantially greater than the
2    reasonable retail market value of the substance.
3    Clause (1) of this subsection (y) shall not apply to a
4noncontrolled substance in its finished dosage form that was
5initially introduced into commerce prior to the initial
6introduction into commerce of a controlled substance in its
7finished dosage form which it may substantially resemble.
8    Nothing in this subsection (y) prohibits the dispensing or
9distributing of noncontrolled substances by persons authorized
10to dispense and distribute controlled substances under this
11Act, provided that such action would be deemed to be carried
12out in good faith under subsection (u) if the substances
13involved were controlled substances.
14    Nothing in this subsection (y) or in this Act prohibits
15the manufacture, preparation, propagation, compounding,
16processing, packaging, advertising or distribution of a drug
17or drugs by any person registered pursuant to Section 510 of
18the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
19    (y-1) "Mail-order pharmacy" means a pharmacy that is
20located in a state of the United States that delivers,
21dispenses or distributes, through the United States Postal
22Service or other common carrier, to Illinois residents, any
23substance which requires a prescription.
24    (z) "Manufacture" means the production, preparation,
25propagation, compounding, conversion or processing of a
26controlled substance other than methamphetamine, either

 

 

SB0218- 52 -LRB103 25028 AMQ 51362 b

1directly or indirectly, by extraction from substances of
2natural origin, or independently by means of chemical
3synthesis, or by a combination of extraction and chemical
4synthesis, and includes any packaging or repackaging of the
5substance or labeling of its container, except that this term
6does not include:
7        (1) by an ultimate user, the preparation or
8    compounding of a controlled substance for his or her own
9    use;
10        (2) by a practitioner, or his or her authorized agent
11    under his or her supervision, the preparation,
12    compounding, packaging, or labeling of a controlled
13    substance:
14            (a) as an incident to his or her administering or
15        dispensing of a controlled substance in the course of
16        his or her professional practice; or
17            (b) as an incident to lawful research, teaching or
18        chemical analysis and not for sale; or
19        (3) the packaging, repackaging, or labeling of drugs
20    only to the extent permitted under the Illinois Drug Reuse
21    Opportunity Program Act.
22    (z-1) (Blank).
23    (z-5) "Medication shopping" means the conduct prohibited
24under subsection (a) of Section 314.5 of this Act.
25    (z-10) "Mid-level practitioner" means (i) a physician
26assistant who has been delegated authority to prescribe

 

 

SB0218- 53 -LRB103 25028 AMQ 51362 b

1through a written delegation of authority by a physician
2licensed to practice medicine in all of its branches, in
3accordance with Section 7.5 of the Physician Assistant
4Practice Act of 1987, (ii) an advanced practice registered
5nurse who has been delegated authority to prescribe through a
6written delegation of authority by a physician licensed to
7practice medicine in all of its branches or by a podiatric
8physician, in accordance with Section 65-40 of the Nurse
9Practice Act, (iii) an advanced practice registered nurse
10certified as a nurse practitioner, nurse midwife, or clinical
11nurse specialist who has been granted authority to prescribe
12by a hospital affiliate in accordance with Section 65-45 of
13the Nurse Practice Act, (iv) an animal euthanasia agency, or
14(v) a prescribing psychologist.
15    (aa) "Narcotic drug" means any of the following, whether
16produced directly or indirectly by extraction from substances
17of vegetable origin, or independently by means of chemical
18synthesis, or by a combination of extraction and chemical
19synthesis:
20        (1) opium, opiates, derivatives of opium and opiates,
21    including their isomers, esters, ethers, salts, and salts
22    of isomers, esters, and ethers, whenever the existence of
23    such isomers, esters, ethers, and salts is possible within
24    the specific chemical designation; however the term
25    "narcotic drug" does not include the isoquinoline
26    alkaloids of opium;

 

 

SB0218- 54 -LRB103 25028 AMQ 51362 b

1        (2) (blank);
2        (3) opium poppy and poppy straw;
3        (4) coca leaves, except coca leaves and extracts of
4    coca leaves from which substantially all of the cocaine
5    and ecgonine, and their isomers, derivatives and salts,
6    have been removed;
7        (5) cocaine, its salts, optical and geometric isomers,
8    and salts of isomers;
9        (6) ecgonine, its derivatives, their salts, isomers,
10    and salts of isomers;
11        (7) any compound, mixture, or preparation which
12    contains any quantity of any of the substances referred to
13    in subparagraphs (1) through (6).
14    (bb) "Nurse" means a registered nurse licensed under the
15Nurse Practice Act.
16    (cc) (Blank).
17    (dd) "Opiate" means any substance having an addiction
18forming or addiction sustaining liability similar to morphine
19or being capable of conversion into a drug having addiction
20forming or addiction sustaining liability.
21    (ee) "Opium poppy" means the plant of the species Papaver
22somniferum L., except its seeds.
23    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
24solution or other liquid form of medication intended for
25administration by mouth, but the term does not include a form
26of medication intended for buccal, sublingual, or transmucosal

 

 

SB0218- 55 -LRB103 25028 AMQ 51362 b

1administration.
2    (ff) "Parole and Pardon Board" means the Parole and Pardon
3Board of the State of Illinois or its successor agency.
4    (gg) "Person" means any individual, corporation,
5mail-order pharmacy, government or governmental subdivision or
6agency, business trust, estate, trust, partnership or
7association, or any other entity.
8    (hh) "Pharmacist" means any person who holds a license or
9certificate of registration as a registered pharmacist, a
10local registered pharmacist or a registered assistant
11pharmacist under the Pharmacy Practice Act.
12    (ii) "Pharmacy" means any store, ship or other place in
13which pharmacy is authorized to be practiced under the
14Pharmacy Practice Act.
15    (ii-5) "Pharmacy shopping" means the conduct prohibited
16under subsection (b) of Section 314.5 of this Act.
17    (ii-10) "Physician" (except when the context otherwise
18requires) means a person licensed to practice medicine in all
19of its branches.
20    (jj) "Poppy straw" means all parts, except the seeds, of
21the opium poppy, after mowing.
22    (kk) "Practitioner" means a physician licensed to practice
23medicine in all its branches, dentist, optometrist, podiatric
24physician, veterinarian, scientific investigator, pharmacist,
25physician assistant, advanced practice registered nurse,
26licensed practical nurse, registered nurse, emergency medical

 

 

SB0218- 56 -LRB103 25028 AMQ 51362 b

1services personnel, hospital, laboratory, or pharmacy, or
2other person licensed, registered, or otherwise lawfully
3permitted by the United States or this State to distribute,
4dispense, conduct research with respect to, administer or use
5in teaching or chemical analysis, a controlled substance in
6the course of professional practice or research.
7    (ll) "Pre-printed prescription" means a written
8prescription upon which the designated drug has been indicated
9prior to the time of issuance; the term does not mean a written
10prescription that is individually generated by machine or
11computer in the prescriber's office.
12    (mm) "Prescriber" means a physician licensed to practice
13medicine in all its branches, dentist, optometrist,
14prescribing psychologist licensed under Section 4.2 of the
15Clinical Psychologist Licensing Act with prescriptive
16authority delegated under Section 4.3 of the Clinical
17Psychologist Licensing Act, podiatric physician, or
18veterinarian who issues a prescription, a physician assistant
19who issues a prescription for a controlled substance in
20accordance with Section 303.05, a written delegation, and a
21written collaborative agreement required under Section 7.5 of
22the Physician Assistant Practice Act of 1987, an advanced
23practice registered nurse with prescriptive authority
24delegated under Section 65-40 of the Nurse Practice Act and in
25accordance with Section 303.05, a written delegation, and a
26written collaborative agreement under Section 65-35 of the

 

 

SB0218- 57 -LRB103 25028 AMQ 51362 b

1Nurse Practice Act, an advanced practice registered nurse
2certified as a nurse practitioner, nurse midwife, or clinical
3nurse specialist who has been granted authority to prescribe
4by a hospital affiliate in accordance with Section 65-45 of
5the Nurse Practice Act and in accordance with Section 303.05,
6or an advanced practice registered nurse certified as a nurse
7practitioner, nurse midwife, or clinical nurse specialist who
8has full practice authority pursuant to Section 65-43 of the
9Nurse Practice Act.
10    (nn) "Prescription" means a written, facsimile, or oral
11order, or an electronic order that complies with applicable
12federal requirements, of a physician licensed to practice
13medicine in all its branches, dentist, podiatric physician or
14veterinarian for any controlled substance, of an optometrist
15in accordance with Section 15.1 of the Illinois Optometric
16Practice Act of 1987, of a prescribing psychologist licensed
17under Section 4.2 of the Clinical Psychologist Licensing Act
18with prescriptive authority delegated under Section 4.3 of the
19Clinical Psychologist Licensing Act, of a physician assistant
20for a controlled substance in accordance with Section 303.05,
21a written delegation, and a written collaborative agreement
22required under Section 7.5 of the Physician Assistant Practice
23Act of 1987, of an advanced practice registered nurse with
24prescriptive authority delegated under Section 65-40 of the
25Nurse Practice Act who issues a prescription for a controlled
26substance in accordance with Section 303.05, a written

 

 

SB0218- 58 -LRB103 25028 AMQ 51362 b

1delegation, and a written collaborative agreement under
2Section 65-35 of the Nurse Practice Act, of an advanced
3practice registered nurse certified as a nurse practitioner,
4nurse midwife, or clinical nurse specialist who has been
5granted authority to prescribe by a hospital affiliate in
6accordance with Section 65-45 of the Nurse Practice Act and in
7accordance with Section 303.05 when required by law, or of an
8advanced practice registered nurse certified as a nurse
9practitioner, nurse midwife, or clinical nurse specialist who
10has full practice authority pursuant to Section 65-43 of the
11Nurse Practice Act.
12    (nn-5) "Prescription Information Library" (PIL) means an
13electronic library that contains reported controlled substance
14data.
15    (nn-10) "Prescription Monitoring Program" (PMP) means the
16entity that collects, tracks, and stores reported data on
17controlled substances and select drugs pursuant to Section
18316.
19    (oo) "Production" or "produce" means manufacture,
20planting, cultivating, growing, or harvesting of a controlled
21substance other than methamphetamine.
22    (pp) "Registrant" means every person who is required to
23register under Section 302 of this Act.
24    (qq) "Registry number" means the number assigned to each
25person authorized to handle controlled substances under the
26laws of the United States and of this State.

 

 

SB0218- 59 -LRB103 25028 AMQ 51362 b

1    (qq-5) "Secretary" means, as the context requires, either
2the Secretary of the Department or the Secretary of the
3Department of Financial and Professional Regulation, and the
4Secretary's designated agents.
5    (rr) "State" includes the State of Illinois and any state,
6district, commonwealth, territory, insular possession thereof,
7and any area subject to the legal authority of the United
8States of America.
9    (rr-5) "Stimulant" means any drug that (i) causes an
10overall excitation of central nervous system functions, (ii)
11causes impaired consciousness and awareness, and (iii) can be
12habit-forming or lead to a substance abuse problem, including,
13but not limited to, amphetamines and their analogs,
14methylphenidate and its analogs, cocaine, and phencyclidine
15and its analogs.
16    (rr-10) "Synthetic drug" includes, but is not limited to,
17any synthetic cannabinoids or piperazines or any synthetic
18cathinones as provided for in Schedule I.
19    (ss) "Ultimate user" means a person who lawfully possesses
20a controlled substance for his or her own use or for the use of
21a member of his or her household or for administering to an
22animal owned by him or her or by a member of his or her
23household.
24(Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22;
25102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)
 

 

 

SB0218- 60 -LRB103 25028 AMQ 51362 b

1    (720 ILCS 570/303.05)
2    Sec. 303.05. Mid-level practitioner registration.
3    (a) The Department of Financial and Professional
4Regulation shall register licensed physician assistants,
5licensed advanced practice registered nurses, and prescribing
6psychologists licensed under Section 4.2 of the Clinical
7Psychologist Licensing Act to prescribe and dispense
8controlled substances under Section 303 and euthanasia
9agencies to purchase, store, or administer animal euthanasia
10drugs under the following circumstances:
11        (1) with respect to physician assistants,
12            (A) the physician assistant has been delegated
13        written authority to prescribe any Schedule III
14        through V controlled substances by a physician
15        licensed to practice medicine in all its branches in
16        accordance with Section 7.5 of the Physician Assistant
17        Practice Act of 1987; and the physician assistant has
18        completed the appropriate application forms and has
19        paid the required fees as set by rule; or
20            (B) the physician assistant has been delegated
21        authority by a collaborating physician licensed to
22        practice medicine in all its branches to prescribe or
23        dispense Schedule II controlled substances through a
24        written delegation of authority and under the
25        following conditions:
26                (i) Specific Schedule II controlled substances

 

 

SB0218- 61 -LRB103 25028 AMQ 51362 b

1            by oral dosage or topical or transdermal
2            application may be delegated, provided that the
3            delegated Schedule II controlled substances are
4            routinely prescribed by the collaborating
5            physician. This delegation must identify the
6            specific Schedule II controlled substances by
7            either brand name or generic name. Schedule II
8            controlled substances to be delivered by injection
9            or other route of administration may not be
10            delegated;
11                (ii) any delegation must be of controlled
12            substances prescribed by the collaborating
13            physician;
14                (iii) all prescriptions must be limited to no
15            more than a 30-day supply, with any continuation
16            authorized only after prior approval of the
17            collaborating physician;
18                (iv) the physician assistant must discuss the
19            condition of any patients for whom a controlled
20            substance is prescribed monthly with the
21            delegating physician;
22            (A) (v) the physician assistant must have
23        completed the appropriate application forms and paid
24        the required fees as set by rule;
25            (B) (vi) the physician assistant must provide
26        evidence of satisfactory completion of 45 contact

 

 

SB0218- 62 -LRB103 25028 AMQ 51362 b

1        hours in pharmacology from any physician assistant
2        program accredited by the Accreditation Review
3        Commission on Education for the Physician Assistant
4        (ARC-PA), or its predecessor agency, for any new
5        license issued with Schedule II authority after the
6        effective date of this amendatory Act of the 97th
7        General Assembly; and
8            (C) (vii) the physician assistant must annually
9        complete at least 5 hours of continuing education in
10        pharmacology;
11        (2) with respect to advanced practice registered
12    nurses who do not meet the requirements of Section 65-43
13    of the Nurse Practice Act,
14            (A) the advanced practice registered nurse has
15        been delegated authority to prescribe any Schedule III
16        through V controlled substances by a collaborating
17        physician licensed to practice medicine in all its
18        branches or a collaborating podiatric physician in
19        accordance with Section 65-40 of the Nurse Practice
20        Act. The advanced practice registered nurse has
21        completed the appropriate application forms and has
22        paid the required fees as set by rule; or
23            (B) the advanced practice registered nurse has
24        been delegated authority by a collaborating physician
25        licensed to practice medicine in all its branches to
26        prescribe or dispense Schedule II controlled

 

 

SB0218- 63 -LRB103 25028 AMQ 51362 b

1        substances through a written delegation of authority
2        and under the following conditions:
3                (i) specific Schedule II controlled substances
4            by oral dosage or topical or transdermal
5            application may be delegated, provided that the
6            delegated Schedule II controlled substances are
7            routinely prescribed by the collaborating
8            physician. This delegation must identify the
9            specific Schedule II controlled substances by
10            either brand name or generic name. Schedule II
11            controlled substances to be delivered by injection
12            or other route of administration may not be
13            delegated;
14                (ii) any delegation must be of controlled
15            substances prescribed by the collaborating
16            physician;
17                (iii) all prescriptions must be limited to no
18            more than a 30-day supply, with any continuation
19            authorized only after prior approval of the
20            collaborating physician;
21                (iv) the advanced practice registered nurse
22            must discuss the condition of any patients for
23            whom a controlled substance is prescribed monthly
24            with the delegating physician or in the course of
25            review as required by Section 65-40 of the Nurse
26            Practice Act;

 

 

SB0218- 64 -LRB103 25028 AMQ 51362 b

1                (v) the advanced practice registered nurse
2            must have completed the appropriate application
3            forms and paid the required fees as set by rule;
4                (vi) the advanced practice registered nurse
5            must provide evidence of satisfactory completion
6            of at least 45 graduate contact hours in
7            pharmacology for any new license issued with
8            Schedule II authority after the effective date of
9            this amendatory Act of the 97th General Assembly;
10            and
11                (vii) the advanced practice registered nurse
12            must annually complete 5 hours of continuing
13            education in pharmacology;
14        (2.5) with respect to advanced practice registered
15    nurses certified as nurse practitioners, nurse midwives,
16    or clinical nurse specialists who do not meet the
17    requirements of Section 65-43 of the Nurse Practice Act
18    practicing in a hospital affiliate,
19            (A) the advanced practice registered nurse
20        certified as a nurse practitioner, nurse midwife, or
21        clinical nurse specialist has been privileged to
22        prescribe any Schedule II through V controlled
23        substances by the hospital affiliate upon the
24        recommendation of the appropriate physician committee
25        of the hospital affiliate in accordance with Section
26        65-45 of the Nurse Practice Act, has completed the

 

 

SB0218- 65 -LRB103 25028 AMQ 51362 b

1        appropriate application forms, and has paid the
2        required fees as set by rule; and
3            (B) an advanced practice registered nurse
4        certified as a nurse practitioner, nurse midwife, or
5        clinical nurse specialist has been privileged to
6        prescribe any Schedule II controlled substances by the
7        hospital affiliate upon the recommendation of the
8        appropriate physician committee of the hospital
9        affiliate, then the following conditions must be met:
10                (i) specific Schedule II controlled substances
11            by oral dosage or topical or transdermal
12            application may be designated, provided that the
13            designated Schedule II controlled substances are
14            routinely prescribed by advanced practice
15            registered nurses in their area of certification;
16            the privileging documents must identify the
17            specific Schedule II controlled substances by
18            either brand name or generic name; privileges to
19            prescribe or dispense Schedule II controlled
20            substances to be delivered by injection or other
21            route of administration may not be granted;
22                (ii) any privileges must be controlled
23            substances limited to the practice of the advanced
24            practice registered nurse;
25                (iii) any prescription must be limited to no
26            more than a 30-day supply;

 

 

SB0218- 66 -LRB103 25028 AMQ 51362 b

1                (iv) the advanced practice registered nurse
2            must discuss the condition of any patients for
3            whom a controlled substance is prescribed monthly
4            with the appropriate physician committee of the
5            hospital affiliate or its physician designee; and
6                (v) the advanced practice registered nurse
7            must meet the education requirements of this
8            Section;
9        (3) with respect to animal euthanasia agencies, the
10    euthanasia agency has obtained a license from the
11    Department of Financial and Professional Regulation and
12    obtained a registration number from the Department; or
13        (4) with respect to prescribing psychologists, the
14    prescribing psychologist has been delegated authority to
15    prescribe any nonnarcotic Schedule III through V
16    controlled substances by a collaborating physician
17    licensed to practice medicine in all its branches in
18    accordance with Section 4.3 of the Clinical Psychologist
19    Licensing Act, and the prescribing psychologist has
20    completed the appropriate application forms and has paid
21    the required fees as set by rule.
22    (b) The mid-level practitioner shall only be licensed to
23prescribe those schedules of controlled substances for which a
24licensed physician has delegated prescriptive authority,
25except that an animal euthanasia agency does not have any
26prescriptive authority and except that a physician assistant

 

 

SB0218- 67 -LRB103 25028 AMQ 51362 b

1shall have prescriptive authority in accordance with the
2Physician Assistant Practice Act of 1987 without delegation by
3a physician. An A physician assistant and an advanced practice
4registered nurse is are prohibited from prescribing
5medications and controlled substances not set forth in the
6required written delegation of authority or as authorized by
7their practice Act.
8    (c) Upon completion of all registration requirements,
9physician assistants, advanced practice registered nurses, and
10animal euthanasia agencies may be issued a mid-level
11practitioner controlled substances license for Illinois.
12    (d) A collaborating physician may, but is not required to,
13delegate prescriptive authority to an advanced practice
14registered nurse as part of a written collaborative agreement,
15and the delegation of prescriptive authority shall conform to
16the requirements of Section 65-40 of the Nurse Practice Act.
17    (e) (Blank). A collaborating physician may, but is not
18required to, delegate prescriptive authority to a physician
19assistant as part of a written collaborative agreement, and
20the delegation of prescriptive authority shall conform to the
21requirements of Section 7.5 of the Physician Assistant
22Practice Act of 1987.
23    (f) Nothing in this Section shall be construed to prohibit
24generic substitution.
25(Source: P.A. 99-173, eff. 7-29-15; 100-453, eff. 8-25-17;
26100-513, eff. 1-1-18; 100-863, eff. 8-14-18.)